Michael Grissinger

CIK: 0001757601

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

LPCN

Lipocine Inc.

Director

ACET

Adicet Bio, Inc.

Director

APRE

Aprea Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

LPCN
Lipocine Inc.
Aug 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
2K shares at avg. $2.11-
ACET
Adicet Bio, Inc.
Jun 21, 2026
Award(A)
Stock Option (Right to Buy)
Direct
4.2K shares-
APRE
Aprea Therapeutics, Inc.
Jun 16, 2026
Award(A)
Direct
3.1K shares-
APRE
Aprea Therapeutics, Inc.
Jun 5, 2025
Award(A)
Direct
1K shares-
ACET
Adicet Bio, Inc.
Apr 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
70.2K shares-

		Type	Shares	Price		Ownership
Aug 3, 2026	LPCN Lipocine Inc.	Award(A) Stock Option (Right to Buy)	2,000	$2.11	-	Direct
Jun 21, 2026	ACET Adicet Bio, Inc.	Award(A) Stock Option (Right to Buy)	4,200	-	-	Direct
Jun 16, 2026	APRE Aprea Therapeutics, Inc.	Award(A)	3,135	-	$0	Direct
Jun 5, 2025	APRE Aprea Therapeutics, Inc.	Award(A)	1,045	-	-	Direct
Apr 17, 2025	ACET Adicet Bio, Inc.	Award(A) Stock Option (Right to Buy)	70,200	-	-	Direct

1-5 of 5 transactions

About Grissinger Michael

Grissinger Michael (SEC CIK 0001757601) files insider reports with the SEC as Director of Lipocine Inc. (LPCN), Director of Adicet Bio, Inc. (ACET) and Director of Aprea Therapeutics, Inc. (APRE).

Signal8 holds 7 ownership filings by Grissinger Michael (2 Form 3, 5 Form 4), filed between Apr 21, 2025 and Aug 7, 2026. Those filings report 5 transactions, from Apr 17, 2025 to Aug 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Grissinger Michael's filings is in SALT LAKE CITY, UT.

Recent filings by Grissinger Michael

Aug 3, 2026: Grant or award of LPCN derivative securities (Form 4, code A).
Jun 21, 2026: Grant or award of ACET derivative securities (Form 4, code A).
Jun 16, 2026: Grant or award of APRE shares (Form 4, code A).
Jun 5, 2025: Grant or award of APRE shares (Form 4, code A).
Apr 17, 2025: Grant or award of ACET derivative securities (Form 4, code A).

Other insiders filing for Lipocine Inc. (LPCN)

Higuchi John W., Director
Jene Jill M., Director
Ono Richard Dana, Director
Patel Mahesh V., Chief Executive Officer
Fogarty Krista, Principal Accounting Officer
Papapetropoulos Spyros, Director

How to read Form 4 transaction codes